{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Connor RI"],"funding":["NIAID NIH HHS"],"pagination":["1552-76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC124637"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["72(2)"],"pubmed_abstract":["We have studied 18 participants in phase I/II clinical trials of recombinant gp120 (rgp120) subunit vaccines (MN and SF-2) who became infected with human immunodeficiency virus type 1 (HIV-1) during the course of the trials. Of the 18 individuals, 2 had received a placebo vaccine, 9 had been immunized with MN rgp120, and seven had been immunized with SF-2 rgp120. Thirteen of the 18 infected vaccinees had received three or four immunizations prior to becoming infected. Of these, two were placebo recipients, six had received MN rgp120, and five had received SF-2 rgp120. Only 1 of the 11 rgp120 recipients who had multiple immunizations failed to develop a strong immunoglobulin G antibody response to the immunogen. However, the antibody response to rgp120 was transient, typically having a half"],"journal":["Journal of virology"],"pubmed_title":["Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines."],"pmcid":["PMC124637"],"funding_grant_id":["AI45218"],"pubmed_authors":["Mestecky J","McDonald D","Korber BT","Walker BD","Wolinsky SM","Jackson S","Vermund SH","Fenamore E","McWilliams N","Moore JP","Graham BS","Gao F","Kalams S","Ho DD","Hahn BH","Neumann AU","Connor RI","Kunstman KJ","Trkola A","Cao Y"],"additional_accession":[]},"is_claimable":false,"name":"Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.","description":"We have studied 18 participants in phase I/II clinical trials of recombinant gp120 (rgp120) subunit vaccines (MN and SF-2) who became infected with human immunodeficiency virus type 1 (HIV-1) during the course of the trials. Of the 18 individuals, 2 had received a placebo vaccine, 9 had been immunized with MN rgp120, and seven had been immunized with SF-2 rgp120. Thirteen of the 18 infected vaccinees had received three or four immunizations prior to becoming infected. Of these, two were placebo recipients, six had received MN rgp120, and five had received SF-2 rgp120. Only 1 of the 11 rgp120 recipients who had multiple immunizations failed to develop a strong immunoglobulin G antibody response to the immunogen. However, the antibody response to rgp120 was transient, typically having a half","dates":{"release":"1998-01-01T00:00:00Z","publication":"1998 Feb","modification":"2025-05-31T23:21:55.322Z","creation":"2019-03-27T00:13:18Z"},"accession":"S-EPMC124637","cross_references":{"pubmed":["9445059"],"doi":["10.1128/JVI.72.2.1552-1576.1998"]}}